I really look forward to seeing the outcome of the occupancy study. For me, the biggest unanswered question is the quantifiable inhibition of 11b hsd1.
They theorised in phase 1 that xanamem inhibits 11bhsd1 based on the fact it crosses the blood brain barrier in sufficient concentrations to theoretically inhibit the enzyme.
The theory is sound, but nothing beats quantifiable data. Results due in q2 2019 will most likely be overshadowed by another announcement due around that time I'm thinking.
As for other indications, diabetes always seemed to be the next target. Recent announcements suggests it's all still up in the air though. I trust whatever they choose they will have good reason. Nothing actionable in this announcement but I'm stoked things are moving forward.
ACW Price at posting:
6.1¢ Sentiment: Buy Disclosure: Held
